Carmela Mocerino
YOU?
Author Swipe
View article: New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III
New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III Open
Early breast cancer (EBC) treatment has evolved from radical surgery to a multidisciplinary approach, integrating radiotherapy, chemotherapy, targeted therapy, and hormone therapy with surgery to ensure the best possible outcome. Despite t…
View article: Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients Open
View article: Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study Open
View article: A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial Open
View article: Adjuvant Endocrine Therapy Choices in Premenopausal Patients with Hormone Receptor-Positive Early Breast Cancer: Results from the Prospective Gim23-Poster Study
Adjuvant Endocrine Therapy Choices in Premenopausal Patients with Hormone Receptor-Positive Early Breast Cancer: Results from the Prospective Gim23-Poster Study Open
View article: 1202P Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS)
1202P Final analysis of TENEC trial: A phase II trial of temozolomide (TMZ) as second-line treatment for advanced neuroendocrine carcinomas (NEC) in patients (pts) with a poor performance status (PS) Open
View article: HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study Open
Background: Approximately 45–50% of breast cancers (BCs) have a HER2 immunohistochemical score of 1+ or 2+ with negative in situ hybridization, defining the “HER2-low BC” subtype. No anti-HER2 agents are currently approved for this subgrou…
View article: Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus Open
Somatostatin analogs mantain their major role in the treatment of patients with advanced neuroendocrine tumors (NETs) and have multiple modulatory effects on the immune system. Here, we evaluated the effects of lanreotide treatment on expr…
View article: Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract
Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract Open
Rationale: There is an association between the presence of neuroendocrine neoplasms and incremented risk to develop second primary malignancies. This risk is estimated to be 17%. The most common secondary neoplasms were found in the Gastro…
View article: Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group Open
View article: Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety Open
Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer …
View article: Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Open
View article: Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new results. The multicenter VICTOR-6 study
Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new results. The multicenter VICTOR-6 study Open
View article: Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial) Open
View article: Multidisciplinary approach to breast angiosarcoma in an elderly patient: Repeated local relapses and significant objective responses
Multidisciplinary approach to breast angiosarcoma in an elderly patient: Repeated local relapses and significant objective responses Open
Angiosarcomas are malignant tumors of endovascular origin, which may be divided into primary and secondary forms. Secondary breast angiosarcomas are an increasing problem, especially in patients treated with breast-conserving surgery follo…
View article: Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life
Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life Open
Somatostatin analogues (SSAs) have shown limited and variable antiproliferative effects in neuroendocrine tumours (NETs). Whether tumour control by SSAs depends on grading based on the 2010 WHO NET classification is still unclear. The aim …
View article: Horner’s syndrome: An unusual presentation of metastatic disease in breast cancer
Horner’s syndrome: An unusual presentation of metastatic disease in breast cancer Open
Horner’s syndrome (HS) is caused by an interruption of the cervical sympathetic pathway to the eye and the face. Acquired HS is mainly caused by benign or malignant neoplasms, and in patients with a history of cancer, it is almost always t…
View article: Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score
Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score Open
We read with interest the review article on management of gastric neuroendocrine tumours (NETs) by Basuroy et al.1 In particular, the authors emphasised the predictive role of ki67 imminohistochemical score on medical management of NETs. T…